Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial
Year: 2025
Type: article
Language: en
Topic: Tuberculosis Research and Epidemiology
Authors and affiliations:
raw_author_name: Jia Miao
raw_affiliation_strings: GCP Center/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China
GCP Center/Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Zhenling Wang
raw_affiliation_strings: Laboratory of Aging Research and Cancer Drug Target National Clinical Research Center for Geriatrics State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University  Chengdu China
Laboratory of Aging Research and Cancer Drug Target, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
raw_author_name: Zhenyu Ding
raw_affiliation_strings: Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Huashan Shi
raw_affiliation_strings: Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Yongping Qin
raw_affiliation_strings: GCP Center/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China
GCP Center/Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Tiantao Gao
raw_affiliation_strings: GCP Center/Institute of Drug Clinical Trials West China Hospital Sichuan University  Chengdu Sichuan China
GCP Center/Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Ning Jiang
raw_affiliation_strings: Jumbo Drug Bank Co., Ltd  Chengdu China
Jumbo Drug Bank Co., Ltd, Chengdu, China
raw_author_name: Jianqing He
raw_affiliation_strings: Department of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital Sichuan University  Chengdu China
Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China
raw_author_name: Manni Wang
raw_affiliation_strings: Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University  Chengdu Sichuan China
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
raw_author_name: Xiawei Wei
raw_affiliation_strings: Jumbo Drug Bank Co., Ltd  Chengdu China
Laboratory of Aging Research and Cancer Drug Target National Clinical Research Center for Geriatrics State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University  Chengdu China
Laboratory of Aging Research and Cancer Drug Target, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Jumbo Drug Bank Co., Ltd, Chengdu, China